AbbVie Inc. (ABBV)
Health Care · Biotechnology · US stock · S&P 500 component
$285.19
▲ +0.39 (0.14%)
Fair valueFair
$241 −15.3% to fair value
$121fair band $206–$293$362
Day's range
$278.01 – $285.74
52-week range
$190.75 – $291.40
Red flags⚠ Negative equity⚠ Negative equity⚠ Negative equity⚠ Negative equity⚠ Negative equity
About AbbVie Inc.
AbbVie is a research-based biopharmaceutical company. Its medicines treat conditions in immunology, oncology, neuroscience and eye care, and its aesthetics business includes Botox. Skyrizi, Rinvoq and Humira are among its major immunology products. Customers are wholesalers, pharmacies, hospitals and health systems, which in turn supply patients, and the company operates globally with a heavy emphasis on research and development.
AbbVie earns money from prescription medicines and aesthetics products, which are protected for periods by patents. Revenue is $64.4 billion over the last twelve months, with revenue growth over three years of 1.8% a year. The operating margin is 26.2%, and the business earns a profit of 21% on the capital invested in it. It has net debt of 3.8 times EBITDA, and the dividend yield is 2.4%. On the site's X-Ray Score it receives 41 out of 100.
Price chart
52-wk range $190.75 – $291.40Volume 6,172,149Daily, split-adjusted
Vitals
Market cap$505.1B
52-week range$190.75 – $291.40
Volume (last day)6,172,149
P/E (TTM)80.1
EBIT / EV yield3.0%
Free-cash-flow yield3.6%
Dividend yield2.4%
Revenue (TTM)$64.4B
Net income (TTM)$6.3B
Operating margin26.2%
Return on capital21.0%
Debt incl. leases$70.8B
Cash & securities$6.6B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$241middle half of models $225 – $255
Fair
−15.3% to fair value
Average of the 12 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is High, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $285
Undervalued < $206Fair $206 – $293Overvalued > $293
P/E multiple
$272
P/S multiple
$238
EV/EBITDA multiple
$247
EV/EBIT multiple
$245
EV/revenue multiple
$251
10-year DCF, EBITDA exit
$225
5-year DCF, EBITDA exit
$256
10-year DCF, revenue exit
$224
5-year DCF, revenue exit
$254
10-year DCF, growth exit · not used
$86
5-year DCF, growth exit · not used
$82
Dividend discount, stable
$201
Dividend discount, multi-stage
$368
Earnings power value
$117
Growth the price implies
26.8%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Weak
25/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.0%
Free-cash-flow yield3.6%
Fair value vs price0.8×
Growth
Weak
35/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)1.8%
EPS growth (3y)-29.1%
Growth consistency100%
Profitability
Fair
66/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital21.0%
Operating margin26.2%
Gross profitability34.1%
Financial health
Weak
29/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score7 / 9
Net debt / EBITDA3.8×
Interest cover5.8×
Dividends
Fair
52/100
Dividend is typical for its sector.
See the numbers →
Dividend yield2.4%
Dividends vs free cash flow67%
Dividend growth5.1%
Quarterly results: last 6 quarters
+8.4%
Mar '25
+6.6%
Jun '25
+9.1%
Sep '25
+10.0%
Dec '25
+12.4%
Mar '26
+10.2%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $17.0B, diluted EPS $2.03.
Compare with peers
INCY Incyte Corp80 VRTX Vertex Pharmaceuticals...50 AMGN Amgen Inc48 REGN Regeneron Pharmaceutic...47Other Biotechnology companies by X-Ray Score.
SWOT analysis: AbbVie Inc.
Strengthsinside the company
- Return on invested capital is 21.0%, against a median of 12.5% for industry peers.
- Passes 7 of the 9 Piotroski tests, which points to improving profitability, funding and efficiency.
Weaknessesinside the company
- Earnings per share have declined 29.1% a year over three years.
- Net debt is 3.8x EBITDA, above the 3x level that lenders usually watch.
Opportunitiesvaluation and setting
- Revenue growth picked up to 8.6% last year from 1.8% a year over three years.
- Price momentum is strong on the weekly and monthly signals (trends can reverse).
Threatsvaluation and setting
- Heavy debt makes profits sensitive to interest rates and refinancing conditions.
- Trades at 80.0x earnings, 192% above the 27.5x median of industry peers, so the price already assumes better results.
- Valuation uncertainty is high: the models give widely different values, so the fair value range is wide.
- Our checks raised: Negative equity; Negative equity.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare ABBV with peers and sector
Medians of 7 Biotechnology peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): AMGN 48, GILD 37, VRTX 50, REGN 47, MRNA 12, BIIB 44.
| Metric | ABBV | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 41 | 47 | 49 |
| Valuation | 25 | 36 | 55 |
| Growth | 35 | 45 | 48 |
| Profitability | 66 | 39 | 49 |
| Financial health | 29 | 55 | 48 |
| Dividends | 52 | 50 | 50 |
Sector leaders: highest X-Ray Score in Health Care
ABBV ranks #47 of 60 in Health Care and #6 of 8 in Biotechnology by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for ABBV
Each factor is rated by where ABBV stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 6 Good · 5 Average · 10 Bad of 21
Growth: 0 · 1 · 2
Profitability: 3 · 1 · 0
Financial strength: 0 · 1 · 3
Valuation: 0 · 1 · 3
Cash flow: 3 · 0 · 1
Efficiency: 0 · 1 · 1
| Factor | ABBV | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | +1.8% | Bad beats 26% | +5.5% | – | – |
| Revenue growth, last year | +8.6% | Average beats 59% | +7.1% | +3.7% | ▲ Better |
| EPS growth, 3 years a year | −29.1% | Bad beats 3% | +5.0% | – | – |
| Profitability | |||||
| Gross margin | 71.5% | Good beats 75% | 65.0% | 70.0% | ≈ In line |
| Operating margin | 26.2% | Good beats 79% | 16.4% | 24.6% | ≈ In line |
| Net margin | 9.8% | Average beats 47% | 11.1% | 9.0% | ≈ In line |
| Return on invested capital | 21.0% | Good beats 76% | 12.2% | – | – |
| Financial strength | |||||
| Net debt / EBITDA | 3.8x | Bad beats 17% | 2.0x | 3.7x | ≈ In line |
| Interest cover | 5.8x | Bad beats 33% | 9.4x | 5.7x | ≈ In line |
| Current ratio | 0.81 | Bad beats 4% | 1.52 | 0.79 | ≈ In line |
| Piotroski F-score | 7 / 9 | Average beats 62% | 6 / 9 | – | – |
| Valuation | |||||
| P/E ratio | 80.0x | Bad beats 5% | 28.2x | 56.5x | ▼ Worse |
| Price / sales | 7.8x | Bad beats 21% | 3.7x | 5.1x | ▼ Worse |
| EV / EBITDA | 33.8x | Bad beats 15% | 17.6x | 25.2x | ▼ Worse |
| Free cash flow yield | 3.6% | Average beats 36% | 4.4% | 8.0% | ▼ Worse |
| Cash flow | |||||
| Free cash flow margin | 28.3% | Good beats 87% | 16.3% | 39.1% | ▼ Worse |
| Cash from operations / net income | 3.09 | Good beats 91% | 1.61 | 4.40 | ▼ Worse |
| Free cash flow growth, 3 years a year | −9.8% | Bad beats 15% | +4.3% | – | – |
| Accruals (lower is better) | −9.8% | Good beats 85% | −3.9% | – | – |
| Efficiency | |||||
| Inventory turnover | 3.6x | Average beats 64% | 2.9x | 4.9x | ▼ Worse |
| Days sales outstanding | 78 days | Bad beats 14% | 62 days | 71 days | ▼ Worse |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 4 Good · ● 4 Average · ● 8 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldAverage
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverAverage
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 41/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Operating income | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Operating cash flow | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Operating margin | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 2 neutral · 2 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 0 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 281.9 | Bullish |
| EMA 10 | 281.3 | Bullish |
| SMA 20 | 272.9 | Bullish |
| EMA 20 | 275.5 | Bullish |
| SMA 50 | 264.0 | Bullish |
| EMA 50 | 265.3 | Bullish |
| SMA 100 | 252.3 | Bullish |
| EMA 100 | 253.5 | Bullish |
| SMA 200 | 232.1 | Bullish |
| EMA 200 | 238.6 | Bullish |
Oscillators (daily)
| RSI (14) | 65.75 | Neutral |
| MACD (12, 26) | 7.01 | Bullish |
| Momentum (12) | 7.59 | Bullish |
| Stochastic %K (14) | 81.01 | Bearish |
| Williams %R (14) | -18.99 | Bearish |
| CCI (20) | 75.08 | Neutral |
Pivot points (classic, last session)
S3 272.5 | S2 275.3 | S1 280.2 | Pivot 283.0 | R1 288.0 | R2 290.7 | R3 295.7 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
6.92 USD
Yield on today's price
2.43%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 1.7300 | |
| 1.7300 | |
| 1.7300 | |
| 1.7300 | |
| 1.6400 | |
| 1.6400 | |
| 1.6400 | |
| 1.6400 | |
| 1.5500 | |
| 1.5500 | |
| 1.5500 | |
| 1.5500 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold ABBV
| ETF | Share of the fund |
|---|---|
| XLV Health Care Select Sector SPDR | 7.74% |
| IYH iShares U.S. Healthcare | 7.32% |
| FHLC Fidelity MSCI Health Care Index | 6.42% |
| HDV iShares Core High Dividend | 6.16% |
| VHT Vanguard Health Care | 6.09% |
| IXJ iShares Global Healthcare | 5.12% |
| CURE Direxion Daily Healthcare Bull 3X | 5.08% |
| PPH VanEck Pharmaceutical | 4.57% |
The eight funds with the largest weight in ABBV among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
ABBV SEC filings
8-KSEC EDGAR
Director or officer change
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Regulation FD disclosure
8-KSEC EDGAR
Other events
424B5SEC EDGAR
424B5
8-KSEC EDGAR
Other events
424B5SEC EDGAR
424B5
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.